

Supplemental Digital Content 1 - Table 1. Reasons for antiretroviral switches (N=911)

	Total	AZT/3TC/NVP (N=1529)	AZT/3TC/EFV (N=871)	TDF/XTC/NVP (N=630)	TDF/XTC/EFV (N=832)
Toxicity	78	46 (3.0%)	17 (1.9%)	4 (0.06%)	11 (1.3%)
Adverse Effects	62	26 (1.7%)	27 (3.1%)	1 (0.01%)	8 (0.09%)
Poor Adherence	22	13 (0.08%)	6 (0.06%)	3 (0.04%)	0 (0.0%)
Clinical Failure	32	11 (0.07%)	6 (0.06%)	10 (1.5%)	5 (0.06%)
Virological Failure	12	6 (0.03%)	0 (0.0%)	4 (0.06%)	2 (0.02%)
Patient Choice	9	4 (0.02%)	2 (0.02%)	2 (0.03%)	1 (0.01%)
TB	50	19 (1.2%)	6 (0.06%)	23 (3.6%)	2 (0.02%)
Pregnancy	29	4 (0.02%)	9 (1.0%)	6 (0.09%)	10 (1.2%)
Stock Out	71	4 (0.02%)	4 (0.04%)	2 (0.03%)	61 (7.3%)
Other	545	118 (7.7%)	114 (13.0%)	104 (16.5%)	210 (25.2%)
Total Switches	911	251 (16.4%)	191 (21.9%)	159 (25.2%)	310 (37.2%)